<?xml version='1.0' encoding='utf-8'?>
<document id="24748562"><sentence text="The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk."><entity charOffset="47-57" id="DDI-PubMed.24748562.s1.e0" text="Dabrafenib" /></sentence><sentence text="Dabrafenib is a potent ATP-competitive inhibitor for the V600 mutant b-rapidly accelerated fibrosarcoma (b-raf) kinase currently approved in the United States for the treatment of metastatic melanoma"><entity charOffset="0-10" id="DDI-PubMed.24748562.s2.e0" text="Dabrafenib" /></sentence><sentence text=" Studies were conducted in human liver microsomes, recombinant human cytochrome P450 (P450) enzymes, and human hepatocytes to investigate the potential of dabrafenib and its major circulating metabolites to perpetrate pharmacokinetic drug-drug interactions (DDIs) as well as have their own pharmacokinetics affected (victim) by coadministered drugs"><entity charOffset="155-165" id="DDI-PubMed.24748562.s3.e0" text="dabrafenib" /></sentence><sentence text=" Dabrafenib metabolism was mediated by CYP2C8 (56% to 67%) and CYP3A4 (24%); in addition, it has demonstrated inhibition of CYP2C8, 2C9, 2C19, 3A4 (atorvastatin), and (nifedipine), with calculated IC50 values of 8"><entity charOffset="1-11" id="DDI-PubMed.24748562.s4.e0" text="Dabrafenib" /><entity charOffset="168-178" id="DDI-PubMed.24748562.s4.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.24748562.s4.e0" e2="DDI-PubMed.24748562.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24748562.s4.e0" e2="DDI-PubMed.24748562.s4.e1" /></sentence><sentence text="2, 7" /><sentence text="2, 22" /><sentence text="4, 16, and 32 μM" /><sentence text=" It also demonstrated metabolism-dependent inhibition of CYP3A4 with a maximal inactivation rate constant of 0" /><sentence text="040 minute(-1) and a concentration required to achieve half-maximal inactivation for CYP3A4 of 38 μM" /><sentence text=" Hydroxy-dabrafenib inhibited CYP1A2, 2C9, and 3A4 (midazolam) with calculated IC50 values of 83, 29, and 44 μM, and carboxy-dabrafenib did not inhibit any of the P450 enzymes tested"><entity charOffset="1-19" id="DDI-PubMed.24748562.s10.e0" text="Hydroxy-dabrafenib" /></sentence><sentence text=" Desmethyl-dabrafenib inhibited CYP2B6, 2C8, 2C9, 2C19, and 3A4 (midazolam, atorvastatin, and nifedipine) with calculated IC50 values of 78, 47, 6"><entity charOffset="1-21" id="DDI-PubMed.24748562.s11.e0" text="Desmethyl-dabrafenib" /><entity charOffset="65-74" id="DDI-PubMed.24748562.s11.e1" text="midazolam" /><entity charOffset="76-88" id="DDI-PubMed.24748562.s11.e2" text="atorvastatin" /><entity charOffset="94-104" id="DDI-PubMed.24748562.s11.e3" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e0" e2="DDI-PubMed.24748562.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e0" e2="DDI-PubMed.24748562.s11.e1" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e0" e2="DDI-PubMed.24748562.s11.e2" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e0" e2="DDI-PubMed.24748562.s11.e3" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e1" e2="DDI-PubMed.24748562.s11.e1" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e1" e2="DDI-PubMed.24748562.s11.e2" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e1" e2="DDI-PubMed.24748562.s11.e3" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e2" e2="DDI-PubMed.24748562.s11.e2" /><pair ddi="false" e1="DDI-PubMed.24748562.s11.e2" e2="DDI-PubMed.24748562.s11.e3" /></sentence><sentence text="3, 36, 17, 20, and 28 μM, respectively" /><sentence text=" At 30 μM dabrafenib showed increases in CYP2B6 and CYP3A4 mRNA expression indicative of induction"><entity charOffset="10-20" id="DDI-PubMed.24748562.s13.e0" text="dabrafenib" /></sentence><sentence text=" The potential clinical relevance of these findings was explored by using mechanistic static mathematical models to estimate the magnitude of change (area under the curve change) as a result of P450-mediated DDI interactions" /><sentence text=" This risk-assessment approach indicated that dabrafenib is unlikely to perpetrate any in vivo DDIs by inhibition mechanisms, but is a likely inducer of CYP3A4 and a victim of CYP3A4 and CYP2C8 inhibitors"><entity charOffset="46-56" id="DDI-PubMed.24748562.s15.e0" text="dabrafenib" /></sentence><sentence text=" Furthermore, inclusion of the in vitro drug interaction data for dabrafenib metabolites did not impact the overall clinical risk assessment"><entity charOffset="66-76" id="DDI-PubMed.24748562.s16.e0" text="dabrafenib" /></sentence><sentence text=" " /></document>